History

Photocure ASA was founded in 1993 and recruited its fist full-time employee in 1997. Photocure's aim was to commercialise photodynamic technologies developed by the Norwegian Radium Hospital, the largest comprehensive cancer centre in Northern Europe.

Main events since Photocures incorporation include:

	2009	- All rights to Metvix®/Aktilite® sold to Galderma
	2008	- Metvix®/Aktilite® approved in the US
	2007	- Submitted application (sNDA) for approval of Aktilite® in the US
	2006	- Signed licencing agreement with GE Healthcare for Hexvix - Hexvix launched in Europe
	2005	- Hexvix approved in all EU/EEA countries - Hexvix launched in the Nordic region - NDA filed for Hexvix in the US
	2004	- First marketing authorisation obtained for Hexvix
	2003	- Galderma's first Metvix launch
	2002	- First marketing authorisation application filed for Hexvix
	2001	- First marketing authorisation obtained for Metvix - Metvix and Aktilite marketed for the first time - Licensing agreement for Metvix signed with Galderma
	2000	- First marketing authorisation application filed for Metvix - Listing of the company's share on the Oslo Stock Exchange - Start of Hexvix clinical studies
	1997	- Recruited first full-time employee - Start of formal clinical studies for Metvix

Photocure ASA, Hoffsveien 48, NO-0377 Oslo, Norway. Telephone: +47 22 06 22 10 Fax: +47 22 06 22 18